Compugen (CGEN) Earnings Date & Reports

Key Takeaways

• Compugen reported a third quarter 2026 net loss of roughly $5.8 million, or $0.06 per share, narrowing from a $7.0 million loss, or $0.07 per share, a year earlier.
• The loss per share beat consensus estimates of about $0.08, while revenue of approximately $3.8 million roughly doubled year-over-year and came in ahead of expectations.
• Management said the MAIA-Ovarian trial of COM701 is now fully enrolled, with data still expected by the end of the first quarter of 2027.
• The company held about $117.5 million in cash and marketable securities as of September 30, 2026, with a cash runway expected to fund operations into 2029.
• AstraZeneca's Phase III readout for rilvegostomig is now anticipated in the second half of 2027, positioning 2027 as a data-rich year.
• For more information on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore these additional pages.
• Explore Trending AI Robots to discover AI-driven trading strategies currently attracting investor attention.

Earnings Context and Why It Matters

Compugen is a clinical-stage immuno-oncology company that leans on its AI-powered discovery engine to identify novel cancer drug targets. Because it has no commercialized product, its reported financials are driven primarily by partnership payments rather than recurring sales. That makes quarterly earnings less about headline profit and more about balance-sheet strength and clinical execution. Investors scrutinize these reports for signals on trial progress, milestone visibility, and cash runway. With partnered programs from AstraZeneca and Gilead representing potentially more than $1 billion in future milestones and royalties, the third quarter 2026 update offered a fresh look at how quickly those catalysts are advancing and whether Compugen's capital is sufficient to reach key data readouts.

Reported Results

For the third quarter ended September 30, 2026, Compugen reported revenue of approximately $3.8 million, up from roughly $1.9 million in the prior-year period, reflecting recognition of portions of the upfront payment and the investigational new drug (IND) milestone payment under its Gilead license agreement. Research and development (R&D) expenses were approximately $5.8 million, essentially flat year-over-year, while general and administrative (G&A) expenses rose modestly to about $2.3 million from $2.2 million.

The company posted a net loss of roughly $5.8 million, or $0.06 per basic and diluted share, compared with a net loss of about $7.0 million, or $0.07 per share, a year earlier. The result beat consensus estimates of a roughly $0.08 per-share loss, and revenue also landed above analyst expectations. As of September 30, 2026, cash, cash equivalents, short-term bank deposits, and marketable securities totaled approximately $117.5 million.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is built to surface trade ideas, trending stocks, and breakout candidates more efficiently than manual screening, giving investors a faster way to identify opportunities that match their specific criteria. For those tracking companies like Compugen, it offers a structured starting point for deeper research.

Market Reaction and Investor Sentiment

Heading into the report, investor attention was focused less on the bottom line than on clinical catalysts. The confirmation that the MAIA-Ovarian trial of COM701 — a potential first-in-class anti-PVRIG antibody — is fully enrolled was a central positive, keeping the first quarter 2027 data readout on track. The disclosure that AstraZeneca's Phase III ARTEMIDE-Biliary01 readout for rilvegostomig is now expected in the second half of 2027 also shaped sentiment, extending the timeline for a key partnered catalyst. The modest earnings and revenue beats offered limited financial significance given the company's pre-revenue status, but the steady cash position and disciplined spending were viewed as supportive. As a clinical-stage biotech, Compugen's stock remains sensitive to trial outcomes and partner-driven news rather than quarterly profit fluctuations.

Forward Outlook and Key Factors to Monitor

Compugen has positioned 2027 as a pivotal, data-rich year. The most closely watched catalyst is the MAIA-Ovarian readout, expected by the end of the first quarter of 2027. This randomized, placebo-controlled trial evaluates COM701 as maintenance therapy in platinum-sensitive ovarian cancer, a setting with significant unmet need. Investors will be watching whether COM701 can demonstrate a meaningful clinical signal.

On the partnered side, AstraZeneca's rilvegostomig — a PD-1/TIGIT bispecific antibody — is advancing across multiple Phase III trials, with high-level results from ARTEMIDE-Biliary01 now anticipated in the second half of 2027. Compugen remains eligible for up to $195 million in regulatory and commercial milestones plus tiered royalties tied to this asset.

Finally, the Gilead-partnered GS-0321, a potential first-in-class anti-IL-18 binding protein (IL-18BP) antibody, continues its Phase I dose-escalation study. Combined with the newly introduced UnigenX discovery expansion, these programs give Compugen multiple avenues for future value. Key risks to monitor include potential trial delays, partner-driven disclosure timing, and the inherently lumpy nature of milestone-based revenue.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations